

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR MACULAR DEGENERATION</b>
<b>POLICY NUMBER</b>	<b>MP 2.260</b>

<b>CLINICAL BENEFIT</b>	<input type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN. <input checked="" type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. <input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE. <input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. <input type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. <input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
<b>Effective Date:</b>	<b>RETIRED 7/1/2026</b>

[POLICY RATIONALE CODING INFORMATION](#)

[PRODUCT VARIATIONS DEFINITIONS REFERENCES](#)

[DESCRIPTION/BACKGROUND DISCLAIMER POLICY HISTORY](#)

## I. POLICY

Genetic testing for macular degeneration is considered **investigational**. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

### Policy Guidelines

#### Genetics Nomenclature Update

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It was implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). The Society’s nomenclature is recommended by the Human Variome Project, the Human Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology- “pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”-to describe variants identified that cause Mendelian disorders.

**Table PG1. Nomenclature to Report on Variants Found in DNA**

Previous	Updated	Definition
<b>Mutation</b>	Diseased-Assoc.Variant	Disease-associated change in the DNA sequence.
	Variant	Change in DNA sequence

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR MACULAR DEGENERATION</b>
<b>POLICY NUMBER</b>	<b>MP 2.260</b>

	Familial Variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives.
--	------------------	--

**Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification**

<b>Variant Classification</b>	<b>Definition</b>
<b>Pathogenic</b>	Disease-causing change in the DNA sequence
<b>Likely Pathogenic</b>	Likely disease-causing change in the DNA sequence
<b>Variant of uncertain significance</b>	Change in DNA sequence with uncertain effects on disease
<b>Likely benign</b>	Likely benign change in the DNA sequence
<b>Benign</b>	Benign change in the DNA sequence

ACMG: American College of Medical Genetics and Genomics; AMP: Association of Molecular Pathology.

### Genetic Counseling

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

## II. PRODUCT VARIATIONS

[Top](#)

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations as discussed in Section VI. Please see additional information below.

**FEP PPO-** Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

## III. DESCRIPTION/BACKGROUND

[Top](#)

### Macular degeneration

Macular degeneration, the leading cause of severe vision loss in people older than age 60 years, occurs when the central portion of the retina (the macula) deteriorates. Because the disease develops as a person ages, it is often referred to as age-related macular degeneration. In 2019, approximately 19.8 million Americans 40 years of age and older were living with age-related macular degeneration. Sex- and age-standardized rates of age-related macular degeneration were lower for non-Hispanic Black people (7.0%) than for other racial and ethnic groups (13.3%).

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR MACULAR DEGENERATION</b>
<b>POLICY NUMBER</b>	<b>MP 2.260</b>

There are 2 major types of AMD, known as the dry form and the wet form. The dry form is much more common, accounting for 85% to 90% of all cases of AMD, and it is characterized by the buildup of yellow deposits called drusen in the retina and slowly progressive vision loss. The condition typically affects vision in both eyes, although vision loss often occurs in 1 eye before the other. AMD is generally thought to progress along a continuum from dry AMD to neovascular wet AMD, with approximately 10% to 15% of all AMD patients eventually developing the wet form. Occasionally patients with no prior signs of dry AMD present with wet AMD as the first manifestation of the condition.

The wet form of age-related macular degeneration, sometimes referred to as "vision-threatening" or "late stage" age-related macular degeneration, is characterized by the growth of abnormal blood vessels from the choroid underneath the macula and is associated with severe vision loss that can rapidly worsen. The abnormal vessels leak blood and fluid into the retina, which damages the macula, leading to permanent loss of central vision.

Major risk factors for AMD include older age, cigarette smoking, cardiovascular diseases, nutritional factors, and certain genetic markers. Age appears to be the most important risk factor, because the chance of developing the condition increases significantly as a person gets older. Smoking is another established risk factor. Other factors that may increase the risk of AMD include high blood pressure, heart disease, a high-fat diet, or one low in certain nutrients (e.g., antioxidants, zinc), and obesity. Observational data (N=17,174) from the European EYE-RISK Consortium suggest that the odds of age-related macular degeneration increase by at least 2 times in patients with both genetic risk and predisposing lifestyle factors (e.g., smoking and low dietary intake of vegetables, fruit, and fish).

**Clinical Diagnosis**

AMD can be detected by routine eye exam, with one of the most common early signs being the presence of drusen or pigment clumping. An Amsler Grid test, a pattern of straight lines that resembles a checkerboard, may also be used. In an individual with AMD, some of the straight lines may appear wavy or missing.

If AMD is suspected, fluorescein angiography and/or optical coherence tomography (OCT) may be performed. Angiography involves injecting a dye into the bloodstream to identify leaking blood vessels in the macula. OCT captures a cross-sectional image of the macula and aids in identifying fluid beneath the retina and in documenting degrees of retinal thickening.

**Treatment**

There is currently no cure for macular degeneration, but certain treatments may prevent severe vision loss or slow disease progression. For dry AMD, there is no medical treatment; however, changing certain life style risks may slow AMD onset and progression. The goal for wet (advanced) AMD is early detection and treatment aimed at preventing the formation of new blood vessels or sealing the leakage of fluid from blood vessels that have already formed. Treatment options include laser photocoagulation, photodynamic therapy, surgery, anti-angiogenic drugs, and combination treatments. Anti-angiogenesis drugs block the development of new blood vessels and leakage from the abnormal vessels within the eye that cause wet macular degeneration and may lead to patients regaining lost vision. The Age-Related Eye Disease Study

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR MACULAR DEGENERATION</b>
<b>POLICY NUMBER</b>	<b>MP 2.260</b>

(AREDS), a large study performed by the National Eye Institute of the National Institutes of Health, showed that, for certain individuals (those with extensive drusen or neovascular AMD in 1 eye), high doses of vitamins C, E,  $\beta$ -carotene, and zinc may provide a modest protective effect against the progression of AMD.

### Genetic Testing

It has been reported that genetic variants associated with AMD account for approximately 70% of the risk for the condition.

More than 25 genes have been reported to influence the risk of developing AMD, discovered initially through family-based linkage studies, and subsequently through large-scale genome-wide association studies. Genes influencing several biologic pathways, including genetic loci associated with the regulation of complement, lipid, angiogenic, and extracellular matrix pathways, have been found to be associated with the onset, progression, and bilateral involvement of early, intermediate, and advanced stages of AMD.

Loci based on common single-nucleotide variants (SNVs) contribute to the greatest risk of AMD:

- the long (q) arm of chromosome 10 in a region known as 10q26 contains 2 genes of interest, *ARMS2*, and *HTRA1*. Changes in both genes have been studied as possible risk factors for the disease; however, because the 2 genes are so close together, it is difficult to tell which is associated with AMD risk or whether increased risk results from variations in both genes.
- common and rare variants in the complement factor H (*CFH*) gene.

Other confirmed genes in the complement pathway include *C2*, *C3*, *CFB*, and *CFI*.

On the basis of large genome-wide association studies, high-density lipoprotein cholesterol pathway genes have been implicated, including *CETP* and *LIPC*, and possibly *LPL* and *ABCA1*. The collagen matrix pathway genes *COL10A1* and *COL8A1*, apolipoprotein E *APOE*, and the extracellular matrix pathway genes *TIMP3* and *FBN2* have also been linked to AMD. Genes involved in DNA repair (*RAD51B*) and in the angiogenesis pathway (*VEGFA*) have also been associated with AMD.

### Commercially Available Testing for AMD

Commercially available genetic testing for AMD is aimed at identifying those individuals who are at risk of developing *advanced* AMD.

Arctic Medical Laboratories offers Macula Risk®, which uses patient clinical information and the patient's genotype for 15 associated biomarkers in an algorithm to identify whites at high risk for progression of early or intermediate AMD to advanced forms of AMD. A Vita Risk® report is also provided with vitamin recommendations based on the *CFH* and *ARMS2* genotype.

23andMe includes testing for *CFH*, *ARMS2*, and *C2*.

### REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR MACULAR DEGENERATION</b>
<b>POLICY NUMBER</b>	<b>MP 2.260</b>

Clinical Laboratory Improvement Amendments (CLIA). Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of these tests.

### IV. RATIONALE

[Top](#)

#### SUMMARY OF EVIDENCE

For individuals who are asymptomatic with risk of developing AMD who receive genetic testing for AMD, the evidence includes genetic association studies and risk-prediction models. Relevant outcomes are test accuracy, change in disease status, and functional outcomes. The clinical validity of genetic testing appears to provide a small, incremental benefit to risk stratification based on nongenetic risk factors. The clinical utility of genetic testing for AMD is limited, in that there are currently no preventive measures that can be undertaken. No studies have shown improvements in health outcomes in patients identified as being at high risk based on genetic testing. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have AMD who receive genetic testing for AMD, the evidence includes genetic association studies and risk-prediction models. Relevant outcomes are test accuracy, change in disease status, and functional outcomes. The clinical utility of genetic testing in patients who have AMD is limited, in that genetic testing has not been shown to be superior to clinical evaluation in determining the risk of progression of disease. In addition, there is no known association with specific genotypes and specific therapies. The evidence is insufficient to determine the effects of the technology on health outcomes.

### V. DEFINITIONS

[Top](#)

NA

### VI. DISCLAIMER

[Top](#)

*Capital Blue Cross' medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as required by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member's benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the members' benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross' Provider Services or Member Services.*

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR MACULAR DEGENERATION</b>
<b>POLICY NUMBER</b>	<b>MP 2.260</b>

### VII. CODING INFORMATION

[TOP](#)

**Note:** This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

**Investigational when used for Genetic Testing for Macular Degeneration. This includes Tier 2 genetic CPT codes and multianalyte assay with algorithmic analysis (MAAA), when reported:**

Procedure Codes							
0205U	81401	81405	81408	81479	81599		

### VIII. REFERENCES

[TOP](#)

- Centers for Disease Control and Prevention (CDC). Prevalence of Age-Related Macular Degeneration (AMD). Updated October 31, 2022.
- Colijn JM, Meester-Smoor M, Verzijden T, et al. Genetic Risk, Lifestyle, and Age-Related Macular Degeneration in Europe: The EYE-RISK Consortium. *Ophthalmology*. Jul 2021; 128(7): 1039-1049. PMID 33253757
- Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. *Arch Ophthalmol*. Oct 2001; 119(10): 1417-36. PMID 11594942
- Gorin MB. Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics. *Mol Aspects Med*. Aug 2012; 33(4): 467-86. PMID 22561651
- Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. *Lancet*. May 05 2012; 379(9827): 1728-38. PMID 22559899
- Kim IK. Genetic testing for AMD inches forward. 2012
- Hageman GS, Gehrs K, Lejnine S, et al. Clinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degeneration. *Hum Genomics*. Jul 2011; 5(5): 420-40. PMID 21807600
- Jakobsdottir J, Gorin MB, Conley YP, et al. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. *PLoS Genet*. Feb 2009; 5(2): e1000337. PMID 19197355
- Seddon JM, Reynolds R, Maller J, et al. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. *Invest Ophthalmol Vis Sci*. May 2009; 50(5): 2044-53. PMID 19117936
- Seddon JM, Silver RE, Kwong M, et al. Risk Prediction for Progression of Macular Degeneration: 10 Common and Rare Genetic Variants, Demographic, Environmental, and Macular Covariates. *Invest Ophthalmol Vis Sci*. Apr 2015; 56(4): 2192-202. PMID 25655794

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR MACULAR DEGENERATION</b>
<b>POLICY NUMBER</b>	<b>MP 2.260</b>

11. Klein ML, Francis PJ, Ferris FL, et al. Risk assessment model for development of advanced age-related macular degeneration. *Arch Ophthalmol*. Dec 2011; 129(12): 1543-50. PMID 21825180
12. Govindaiah A, Baten A, Smith RT, et al. Optimized Prediction Models from Fundus Imaging and Genetics for Late Age-Related Macular Degeneration. *J Pers Med*. Nov 01 2021; 11(11). PMID 34834479
13. Ajana S, Cougnard-Grégoire A, Colijn JM, et al. Predicting Progression to Advanced Age-Related Macular Degeneration from Clinical, Genetic, and Lifestyle Factors Using Machine Learning. *Ophthalmology*. Apr 2021; 128(4): 587-597. PMID 32890546
14. de Breuk A, Acar IE, Kersten E, et al. Development of a Genotype Assay for Age-Related Macular Degeneration: The EYE-RISK Consortium. *Ophthalmology*. Nov 2021; 128(11): 1604-1617. PMID 32717343
15. Fauser S, Lambrou GN. Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration. *Surv Ophthalmol*. 2015; 60(2): 138-52. PMID 25596882
16. Chew EY, Klein ML, Clemons TE, et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. *Ophthalmology*. Nov 2014; 121(11): 2173-80. PMID 24974817
17. Hagstrom SA, Ying GS, Maguire MG, et al. VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. *Ophthalmology*. Aug 2015; 122(8): 1563-8. PMID 26028346
18. Hagstrom SA, Ying GS, Pauer GJ, et al. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). *JAMA Ophthalmol*. May 2014; 132(5): 521-7. PMID 24652518
19. Awh CC, Lane AM, Hawken S, et al. CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. *Ophthalmology*. Nov 2013; 120(11): 2317-23. PMID 23972322
20. Balikova I, Postelmans L, Pasteels B, et al. Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degeneration. *BMJ Open Ophthalmol*. 2019; 4(1): e000273. PMID 31909188
21. Stone EM, Aldave AJ, Drack AV, et al. Recommendations of the American Academy of Ophthalmology Task Force on Genetic Testing. 2014
22. Flaxel CJ, Adelman RA, Vemulakonda GA, et al; American Academy of Ophthalmology Preferred Practice Pattern (PPP) Retina/Vitreous Committee. Age-Related Macular Degeneration PPP. 2019
23. Csaky KG SA, Kaiser PK, et al. The Use of Genetic Testing in the Management of Patients with Age-Related Macular Degeneration: American Society of Retina Specialists Genetics Task Force Special Report. 2017

### IX. POLICY HISTORY

[Top](#)

<b>MP 2.260</b>	<b>02/28/2020 Consensus Review.</b> No changes to the policy statement. Policy guidelines and references updated.
-----------------	---

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR MACULAR DEGENERATION</b>
<b>POLICY NUMBER</b>	<b>MP 2.260</b>

	<b>10/01/2020 Administrative Update.</b> New code update. Added 0205U effective 10/01/2020.
	<b>04/14/2021 Consensus Review.</b> No change to policy statement. References updated.
	<b>05/25/2022 Consensus Review.</b> Updated FEP, background, and references. No changes to coding.
	<b>06/08/2022 Consensus Review.</b> Updated background and references. No changes to coding.
	<b>05/29/2024 Consensus Review.</b> Updated background and references. No changes to coding.
	<b>07/11/2025 Consensus Review.</b> No changes to the policy statement
	<b>09/24/2025 Administrative Update.</b> Removed Benefit Variations Section and updated Disclaimer.
	<b>03/06/2026 Retirement Review.</b> EviCore Delegation.

[Top](#)

*Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company<sup>®</sup>, Capital Advantage Assurance Company<sup>®</sup> and Keystone Health Plan<sup>®</sup> Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.*